These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
488 related articles for article (PubMed ID: 12935435)
1. Therapeutic and hemolytic evaluation of in-situ liposomal preparation containing amphotericin - beta complexed with different chemically modified beta - cyclodextrins. Chakraborty KK; Naik SR J Pharm Pharm Sci; 2003; 6(2):231-7. PubMed ID: 12935435 [TBL] [Abstract][Full Text] [Related]
2. PHARMACOKINETIC STUDIES OF IN-SITU LIPOSOMAL PREPARATION CONTAINING AMPHOTERICIN B COMPLEXED WITH DIFFERENT CHEMICALLY MODIFIED beta-CYCLODEXTRINS. Chakraborty KK; Naik SR J Liposome Res; 2001; 11(1):1-14. PubMed ID: 19530915 [TBL] [Abstract][Full Text] [Related]
3. In situ liposomal preparation containing amphotericin B: related toxicity and tissue disposition studies. Chakraborty KK; Naik SR Pharm Dev Technol; 2000; 5(4):543-53. PubMed ID: 11109253 [TBL] [Abstract][Full Text] [Related]
4. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. Khan MA; Owais M J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592 [TBL] [Abstract][Full Text] [Related]
5. The novel lipid delivery system of amphotericin B: drug profile and relevance to clinical practice. Rust DM; Jameson G Oncol Nurs Forum; 1998; 25(1):35-48. PubMed ID: 9460772 [TBL] [Abstract][Full Text] [Related]
6. Liposomal amphotericin-B in the control of experimental aspergillosis in mice: Part I--Relative therapeutic efficacy of free and liposomal amphotericin-B. Ahmad I; Sarkar AK; Bachhawat BK Indian J Biochem Biophys; 1989 Dec; 26(6):351-6. PubMed ID: 2698855 [TBL] [Abstract][Full Text] [Related]
7. Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model. Olson JA; Adler-Moore JP; Schwartz J; Jensen GM; Proffitt RT Antimicrob Agents Chemother; 2006 Jun; 50(6):2122-31. PubMed ID: 16723574 [TBL] [Abstract][Full Text] [Related]
8. Incorporation of amphotericin B in tuftsin-bearing liposomes showed enhanced efficacy against systemic cryptococcosis in leucopenic mice. Khan MA; Nasti TH; Owais M J Antimicrob Chemother; 2005 Oct; 56(4):726-31. PubMed ID: 16126780 [TBL] [Abstract][Full Text] [Related]
9. Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis. Gavaldà J; Martín T; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Puigfel Y; Ruiz I; Pahissa A Clin Microbiol Infect; 2005 Dec; 11(12):999-1004. PubMed ID: 16307554 [TBL] [Abstract][Full Text] [Related]
10. Hemolytic and antifungal activity of liposome-entrapped amphotericin B prepared by the precipitation method. Kim JC; Lee EO; Kim JY; Bae SK; Choi TB; Kim JD Pharm Dev Technol; 1997 Aug; 2(3):275-84. PubMed ID: 9552455 [TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Lewis RE; Liao G; Hou J; Chamilos G; Prince RA; Kontoyiannis DP Antimicrob Agents Chemother; 2007 Apr; 51(4):1253-8. PubMed ID: 17261624 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of high doses of liposomal amphotericin B in the treatment of experimental aspergillosis. Martín MT; Gavaldà J; López P; Gomis X; Ramírez JL; Rodríguez D; Len O; Jordano Q; Ruiz I; Rosal M; Almirante B; Pahissa A J Antimicrob Chemother; 2003 Dec; 52(6):1032-4. PubMed ID: 14613950 [TBL] [Abstract][Full Text] [Related]
13. Development of liposomal amphotericin B formulation. Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520 [TBL] [Abstract][Full Text] [Related]
14. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a Guinea pig model of invasive aspergillosis. Kirkpatrick WR; Coco BJ; Patterson TF Antimicrob Agents Chemother; 2006 Apr; 50(4):1567-9. PubMed ID: 16569887 [TBL] [Abstract][Full Text] [Related]
15. [Therapeutic efficiency of amphotericin B liposome modified by RMP-7 to transport drug across blood brain barrier]. Zhang XB; Yuan S; Lei PC; Hou XP Yao Xue Xue Bao; 2004 Apr; 39(4):292-5. PubMed ID: 15303662 [TBL] [Abstract][Full Text] [Related]
16. [A pharmacodynamics study of an intravitreal amphotericin B drug delivery system for the treatment of experimental Aspergillus fumigatus endophthalmitis]. Yang X; Dong XG; Liu AM; Sun SY; Xie LX; Wang SG Zhonghua Yan Ke Za Zhi; 2007 Jun; 43(6):546-53. PubMed ID: 17897534 [TBL] [Abstract][Full Text] [Related]
17. Comparative study on the efficacy of liposomal amphotericin B and voriconazole in a murine pulmonary aspergillosis model. Takemoto K; Yamamoto Y; Ueda Y; Kanazawa K; Yoshida K; Niki Y Chemotherapy; 2009; 55(2):105-13. PubMed ID: 19151551 [TBL] [Abstract][Full Text] [Related]
18. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis. Kretschmar M; Nichterlein T; Hannak D; Hof H Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B. Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826 [TBL] [Abstract][Full Text] [Related]
20. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation. Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]